eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
6/2024
vol. 41
 
Share:
Send email
Share:
Review paper

Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis

Xiaojuan Fu
1
,
Peijie Xu
2
,
Di Lu
3

  1. Chongqing Medical and Pharmaceutical College, Chongqing, China
  2. Chongqing Service Center for Students’ Employment, Innovation and Entrepreneurship, Chongqing, China
  3. Department of Ultrasound, Dianjiang County Hospital of Traditional Chinese Medicine, Chongqing, China
Adv Dermatol Allergol 2024; XLI (6): 560-565
DOI: https://doi.org/10.5114/ada.2024.144166
Online publish date: 2024/11/14
Article file
- Comparative (1).pdf  [0.15 MB]
Get citation
 
 
1. Miyazaki D, Fukagawa K, Okamoto S, et al. Epidemiological aspects of allergic conjunctivitis. Allergol Int 2020; 69: 487-95.
2. Leonardi A, Quintieri L, Presa IJ, et al. Allergic conjunctivitis management: update on ophthalmic solutions. Curr Allergy Asthma Rep 2024; 24: 347-60.
3. Mueller A. Allergic conjunctivitis: an update. Handb Exp Pharmacol 2022; 268: 95-9.
4. Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis 2016; 7: 52-67.
5. Gong L, Sun X, Qu J, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther 2012; 34: 1259-72.
6. Chigbu DI, Coyne AM. Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis. Clin Ophthalmol 2015; 9: 1215-25.
7. Stokes TC, Feinberg G. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis. Clin Exp Allergy 1993; 23: 791-4.
8. Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol 2020; 16: 5.
9. Fukuda K, Ishida W, Wakasa Y, et al. Oral immunotherapy for allergic conjunctivitis using transgenic rice expressing hypoallergenic antigens. Cornea 2018; 37 Suppl 1: S67-73.
10. Renuka, Ranjan A, Sinha AK. Comparative assessment of alcaftadine 0.25%, olopatadine hydrochloride 0.2% and bepotastine besilate 1.5% as anti-allergic conjunctivitis agents. Int J Pharm Clin Res 2021; 13: 412-9.
11. McLaurin EB, Marsico NP, Ackerman SL, et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther 2014; 31: 1059-71.
12. Borazan M, Karalezli A, Akova YA, et al. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthal 2009; 87: 549-54.
13. Mishra MK, Kumari V, Singh RK. A comparative study of efficacy of topical olopatadine (0.1%), bepotastine (1.5%) and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis at Sri Krishna Medical College, Muzaffarpur, Bihar, India. Int J Pharm Clin Res 2022; 14: 553-9.
14. Fujishima H, Hasunuma T, Kawakita T, et al. Efficacy of alcaftadine 0.25% (AGN-229666) for once-daily prevention of cedar-pollen allergic conjunctivitis: a phase 3 randomized study. Ocular Immunol Inflam 2021; 29: 1621-6.
15. Ayyappanavar S, Sridhar S, Kumar K, et al. Comparative analysis of safety and efficacy of alcaftadine 0.25%, olopatadine hydrochloride 0.2% and bepotastine besilate 1.5% in allergic conjunctivitis. Indian J Ophthalmol 2021; 69: 257-61.
16. Kumari P, Prasad V, Najmi MA. In allergic conjunctivitis, comparative assessment of the safety and effectiveness of alcaftadine 0.25 percent, olopatadine hydrochloride 0.2 percent, and bepotastine besilate 1.5 percent. Eur J Mol Clin Med 2020; 7: 4550-6.
17. Singh W, Pandey ML, Rana MK, Chugh K. Comparative Study between the effectiveness and associated adverse effects of olopatadine and alcaftadine when used in treating allergic conjunctivitis in a Tertiary Eye Care Centre of Northern India. J Pharm Neg Results 2022; 13: 3815-20.
18. Krishnan A, Jayanthi C, Sridhar S. A comparative study of efficacy and safety of alcaftadine 0.25% versus olopatadine hydrochloride 0.2% in allergic conjunctivitis at a tertiary care hospital, Kerala. J Ophthalmol 2022; 34: 227-33.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
20. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration 2011.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
22. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Inter Med 2001; 135: 982-9.
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
24. Dudeja L, Janakiraman A, Dudeja I, et al. Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. Indian J Ophthalmol 2019; 67: 1400-4.
25. Agarwal G. A comparative assessment of topical olopatadine (0.1%) and alcaftadine (0.25%) in cases of allergic conjunctivitis. J Adv Med Dent Sci Res 2017; 5: 107-10.
26. Ackerman S, D’Ambrosio F Jr, Greiner JV, et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy 2013; 6: 43-52.
27. Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 2011; 5: 87-93.
28. Bonini S. Atopic keratoconjunctivitis. Allergy 2004; 59 Suppl 78: 71-3.
29. Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Design Develop Ther 2011; 5: 577-84.
30. Nakatani H, Gomes P, Bradford R, et al. Alcaftadine 0.25% versus olopatadine 0.1% in preventing cedar pollen allergic conjunctivitis in Japan: a randomized study. Ocular Immunol Inflam 2019; 27: 622-31.
31. Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
32. J Ocular Pharmacol Ther 2011; 27: 385-93.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.